Congenital Plasminogen Deficiency

Global biopharma company encourages education and awareness around a rare bleeding disorder. FORT LEE, N.J., Oct. 10, 2023 /PRNewswire/ -- Kedrion Biopharma, an international biopharmaceutical company specializing in the production and distribution of plasma-derived therapeutic products used in treating rare and serious diseases, is proud to recognize the fourth Hereditary Factor X (10) Deficiency Awareness Day on October 10, 2023. This day helps bring awareness to a rare bleeding disorder, the patients it impacts, their challenges, and the treatments that can help. Continue Reading Factor X Day was launched on 10/1020 by U.K.-based Bio Products Laboratory (BPL). In 2022, Kedrion joined forces with BPL. The new Kedrion is a global player in plasma derivatives and rare disease medicines, employing more than 5,000 people worldwide. Kedrion Biopharma is proud to recognize the fourth Hereditary Factor X (10) Deficiency Awareness Day on October 10, 2023 Tweet this About one in a million people have hereditary factor X deficiency, which causes unusual or excessive bleeding or bruising, heavy menstrual bleeding in women, painful or swollen joints, nose bleeds, and bleeding gums. Although the disorder is ultra-rare, some patients with severe factor X deficiency could experience life-threatening complications like bleeding in the brain or stomach. Because symptoms vary, patients may suffer for years before being diagnosed. A simple blood test can determine whether someone has the disorder and can be treated with plasma-based treatments. John, one of the oldest known patients with severe hereditary factor X deficiency at age 51, says it best. "Since being diagnosed when I was a year old, I have had to go to the hospital about 150 times for transfusions of fresh frozen plasma to treat bleeds that were not controlled by themselves. As someone living with hereditary factor X deficiency, I want everyone to be more aware of this rare disease and why it is so important to get care and treatment." "We are excited for the first Hereditary Factor X Deficiency Awareness Day since Kedrion joined forces with Bio Products Laboratory in 2022," said Bob Rossilli, Chief Commercial Officer for Kedrion Biopharma. "With over 60 years of combined expertise across the United Kingdom, United States, and Italy, we are delighted to continue raising awareness for hereditary factor X deficiency and providing therapies to support patients, their caregivers, and families on the journey from diagnosis to treatment." Kedrion is committed to providing therapies for rare diseases to improve patients' health as they manage bleeding disorders like hereditary factor X deficiency. To learn more about hereditary factor X deficiency, visit . About Kedrion Kedrion Biopharma is a global biopharmaceutical company that collects and fractionates blood plasma to produce and distribute plasma-derived therapies for use in treating and preventing serious diseases, disorders, and conditions like plasminogen deficiency, hereditary factor X deficiency, and hemophilia. Its portfolio of 37 life-saving products is distributed in over 100 countries. kedrion.com Contact Information: Sandy Sklareski Communications Manager [email protected] 551-255-6557 SOURCE Kedrion Biopharma

FORT LEE, N.J., July 25, 2023 /PRNewswire/ -- Kedrion Biopharma, an international biopharmaceutical company specializing in the production and distribution of plasma-derived therapeutic products used in treating rare and serious diseases recently announced its support of the Immune Deficiency Foundation (IDF) Research Grant Program for the second year in a row. Bioproducts Laboratory (BPL), a UK-based company with over 60 years of experience in the supply of high-quality plasma-derived medicines for the treatment of rare diseases, first provided the grant in 2022. That same year, Kedrion joined forces with BPL to form the new Kedrion. Continue Reading The IDF Research Grant Program is designed to encourage and support patient-oriented research on primary immunodeficiencies (PI), including well-defined research projects with a specified benefit for improving the treatment, health, management, or diagnosis of people with primary immunodeficiencies Kedrion Biopharma announced its support of the Immune Deficiency Foundation Research Grant Program for the second year. Tweet this "Once again, we're excited to support IDF's grant program," said Eric Wolford, VP, Global Clinical Research and Operations for Kedrion. "Helping PI patients live healthier, happier lives is a goal we share with IDF, and we are pleased to reflect this ongoing commitment with another year of support for this research grant." According to Tracy Shaw, Chair of IDF's Board of Trustees, "The continuation of this partnership represents our combined commitment to support studies that contribute to the body of medical knowledge in PI. The research funded through this program will advance IDF's mission to improve the diagnosis, treatment, and quality of life of persons with primary immunodeficiencies." Primary immunodeficiencies are a group of more than 450 rare, chronic disorders in which part of the body's immune system is missing or functions improperly. Because one of the most critical functions of the normal immune system is to protect against infection, patients with PI commonly have an increased vulnerability to recurrent and sometimes severe and debilitating infections. For more information about the IDF Research Grant Program, contact Christopher Scalchunes at [email protected]. About Kedrion Biopharma Kedrion Biopharma is a global biopharmaceutical company that collects and fractionates blood plasma to produce and distribute plasma-derived therapies for use in treating and preventing serious diseases, disorders, and conditions like plasminogen deficiency and hemophilia. Its portfolio of 37 life-saving products is distributed in over 100 countries. kedrion.com About the Immune Deficiency Foundation The Immune Deficiency Foundation (IDF), founded in 1980, is the leading source of information for people looking for answers to questions about PI. Whether you've been recently diagnosed, you've been living with PI for years, or you think you may have PI, we are here to help. IDF offers programs designed to engage, connect, and empower families to live longer, stronger, and healthier lives. primaryimmune.org SOURCE Kedrion Biopharma

Kedrion joined forces with BPL in 2022 This is the first ever approval for a BPL product in China The China Albumin market is the world's largest Launch commenced in April 2023 FORT LEE, N.J., July 12, 2023 /PRNewswire/ -- Kedrion Biopharma, an international biopharmaceutical company specializing in the production and distribution of plasma-derived therapeutic products used in treating rare and serious diseases, has announced that China's National Institutes for Food and Drug Control (NIFDC) has approved BPL's human Albumin product for release to the Chinese market. In 2022, Kedrion joined forces with BPL, a UK-based company with over 60 years of experience in the supply of high-quality plasma-derived medicines for the treatment of rare diseases. As the first ever approval for a BPL product in China, this a major milestone for the company, which can now ship to the country on a regular basis. China is by far the largest human Albumin market in the world of 627 tons vs global demand of 1,368 tons in 20211. "We are delighted to be able to provide this product to patients in China," said Bob Rossilli, Chief Commercial Officer for Kedrion Biopharma. "Obtaining this important license and full distribution agreement in China reflects strongly on our current plan for global expansion while highlighting our corporate mission of providing plasma-derived products worldwide, supporting both healthcare professionals and patients every day." Zhou Xianfeng, Chairman of Board, Hangzhou Jiansheng Medicine Co. Ltd. said, "We are delighted to have partnered with BPL and Kedrion, which are truly committed to making therapies available in all parts of the world by expanding into important new markets such as China." Kedrion places a high value on the welfare of those who benefit from its products, as well as the communities and individuals with whom it collaborates, and works on a global scale to broaden access to plasma therapies. About Kedrion Kedrion Biopharma is a biopharmaceutical company that collects and fractionates blood plasma to produce and distribute worldwide plasma-derived therapies for use in treating and preventing rare and debilitating conditions like Coagulation and Neurological Disorders, Primary and Secondary Immunodeficiencies, and Rh sensitization, which can lead to Hemolytic Disease of the Fetus and Newborn. In 2022, Kedrion joined forces with BPL (Bio Products Laboratory). Based in the United Kingdom, BPL has over 60 years of experience in the supply of high-quality plasma-derived medicines to treat rare diseases. With the combination of Kedrion and BPL, Kedrion is a global player in plasma derivatives and rare disease medicines employing more than 5,000 people worldwide. The company has a plasma collection footprint of 73 centers operated by KEDPLASMA in the United States, and of 5 centers operated by UNICAplasma in the Czech Republic, and a portfolio of 37 products distributed in over 100 countries around the world. With these figures, Kedrion is the world's 5th top player in the field of plasma-derived products. In 2021, Kedrion's acquisition of Prometic, and of its first-ever therapy for Congenital Plasminogen Deficiency, has confirmed our commitment to fighting rare, or even extremely rare, diseases. We act as a bridge between donors and the people who need treatment, and work on a global scale to expand patient access to plasma-derived therapies. kedrion.com Contact Information: Sandy Sklareski Communications Manager s.sklareski@kedrion.com 551-255-6557 1 MRB Reports (MRB Asia Pacific 2021) View original content to download multimedia: SOURCE Kedrion Biopharma